華伍股份(300095.SZ):海外工業制動器業務收入佔整體營收比例較小
格隆匯6月13日丨華伍股份(300095.SZ)於投資者互動平臺表示,公司海外工業制動器業務收入佔整體營收比例較小,主要客戶分佈於韓國、迪拜、新加坡、土耳其、德國等國家和地區,產品以工業制動器備件爲主,公司目前未在伊朗開展相關業務。作爲國內工業制動器領域的領先企業,公司正積極推動全球化戰略佈局,依託境外控股子公司瑞士福爾卡作爲海外拓展平臺,重點開發港口機械、風電及軌道交通等領域的國際市場。未來,公司將進一步完善海外營銷網絡和服務體系,提升全球競爭力,加快實現從“中國領先”到“全球領先”的戰略跨越。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.